Table 3.
In vitro antiproliferative activities of compounds 1–7 against MCF-7, HCT-116 and A549 cells.
| Compounds | IC50 (µM) | ||
|---|---|---|---|
| MCF-7 | HCT-116 | A549 | |
| 1 | 9.23 ± 0.26 | 7.33 ± 0.19 | 5.13 ± 0.18 |
| 2 | 5.88 ± 0.21 | 5.43 ± 0.18 | 7.75 ± 0.11 |
| 3 | 9.17 ± 0.35 | 8.18 ± 0.37 | 5.44 ± 0.21 |
| 4 | 10.77 ± 0.32 | 8.28 ± 0.32 | 6.80 ± 0.18 |
| 5 | 18.44 ± 0.61 | 11.17 ± 0.30 | 8.76 ± 0.29 |
| 6 | 16.24 ± 0.61 | 14.24 ± 0.61 | 10.28 ± 0.27 |
| 7 | 18.14 ± 0.61 | 14.96 ± 0.46 | 9.33 ± 0.23 |
| Erlotinib | 22.46 ± 1.77 | 15.76 ± 1.60 | 18.55 ± 1.70 |
| Doxorubicin | 7.25 ± 0.46 | 5.12 ± 0.21 | NT |
NT: Compounds not investigated. (IC50 values are reported in the mean ± S.D).